CoChat
Sign Up
Cited by 22Cancer Immunotherapy and BiomarkersInflammasome and immune disordersCytokine Signaling Pathways and Interactions

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A review of canakinumab and its therapeutic potential for non-small cell lung cancer

Schenk, Kara M., Reuss, Joshua E., Choquette, Karin, Spira, Alexander I.·2019·Anti-Cancer Drugs
DOI 10.1097/cad.0000000000000832
Open this paper in CoChat — free account

Abstract

Inflammation is essential for our innate and adaptive immunity, but chronic inflammation can also be detrimental, playing a role in tumor development and subversion of host immunity. A multitude of proteins and cytokines are involved in chronic inflammation; interleukin-1β, in particular, has been recognized as a critical pro-inflammatory cytokine that can trigger a cascade of inflammatory mediators, promoting angiogenesis, tumor invasiveness, and metastasis. The inhibition of interleukin-1β with the antibody canakinumab was recently highlighted in a large-scale trial studying the effects of the inflammatory modulating antibody in heart disease. In this study, a marked decrease in the incidence of lung cancer (a 67% relative risk reduction) was observed in a high-risk population. Although a number of preclinical studies have demonstrated that canakinumab inhibits interleukin-1β and reduces inflammation, the question remains whether these actions positively affect both cancer incidence and recurrence. This review will summarize the role of inflammation in cancer propagation and development, discuss the biological rationale for targeting interleukin-1β in lung cancer, advocate for further investigation of the anti-inflammatory antibody canakinumab as a new attractive mechanism for future lung cancer therapy, and discuss future and ongoing trials.

Overview

Integrity signals

Registry

Crossref · 10.1097/cad.0000000000000832

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 53

  1. Jin, 2016, Comparison of the 7th and proposed 8th editions of the AJCC/UICC TNM staging system for non-small cell lung cancer undergoing radical surgery., Sci Rep, 6, 33587, 10.1038/srep33587 · DOI
  2. Barlesi, 2016, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the french cooperative thoracic intergroup (IFCT)., Lancet, 387, 1415, 10.1016/S0140-6736(16)00004-0 · DOI
  3. Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer., N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643 · DOI · Paper page
  4. Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial., Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 · DOI · Paper page
  5. Fehrenbacher, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial., Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 · DOI · Paper page
  6. Lin, 2016, Resisting resistance: targeted therapies in lung cancer., Trends Cancer, 2, 350, 10.1016/j.trecan.2016.05.010 · DOI
  7. Apte, 2006, The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions., Cancer Metastasis Rev, 25, 387, 10.1007/s10555-006-9004-4 · DOI
  8. Grivennikov, 2010, Immunity, inflammation, and cancer., Cell, 140, 883, 10.1016/j.cell.2010.01.025 · DOI · Paper page
  9. Idris, 2015, Interleukin 1β-A potential salivary biomarker for cancer progression?, Biomark Cancer, 7, 25, 10.4137/BIC.S25375 · DOI
  10. Porta, 2009, Cellular and molecular pathways linking inflammation and cancer., Immunobiology, 214, 761, 10.1016/j.imbio.2009.06.014 · DOI
  11. Dinarello, 2012, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases., Nat Rev Drug Discov, 11, 633, 10.1038/nrd3800 · DOI
  12. Bent, 2018, Interleukin-1 beta—a friend or foe in malignancies?, Int J Mol Sci, 19, ii, 10.3390/ijms19082155 · DOI
  13. Alten, 2008, The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis., Arthritis Res Ther, 10, R67, 10.1186/ar2438 · DOI
  14. Chakraborty, 2012, Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody., Clin Pharmacokinet, 51, e1, 10.2165/11599820-000000000-00000 · DOI
  15. Kuemmerle-Deschner, 2013, Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians., Ther Adv Musculoskelet Dis, 5, 315, 10.1177/1759720X13502629 · DOI
  16. Church, 2009, Canakinumab, a fully-human mab against IL-1beta for the potential treatment of inflammatory disorders., Curr Opin Mol Ther, 11, 81
  17. Fenini, 2017, Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases., Front Pharmacol, 8, 278, 10.3389/fphar.2017.00278 · DOI
  18. Ridker, 2017, Antiinflammatory therapy with canakinumab for atherosclerotic disease., N Engl J Med, 377, 1119, 10.1056/NEJMoa1707914 · DOI · Paper page
  19. Ridker, 2017, Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial., Lancet, 390, 1833, 10.1016/S0140-6736(17)32247-X · DOI · Paper page
  20. Chaturvedi, 2010, C-reactive protein and risk of lung cancer., J Clin Oncol, 28, 2719, 10.1200/JCO.2009.27.0454 · DOI
  21. Bacha, 2017, Combined C-reactive protein and neutrophil to lymphocyte ratio use predict survival innon-small-cell lung cancer., Tunis Med, 95, 229
  22. Roxburgh, 2010, Role of systemic inflammatory response in predicting survival in patients with primary operable cancer., Future Oncol, 6, 149, 10.2217/fon.09.136 · DOI
  23. Che, 2017, Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE2/β-catenin signalling pathway., Mol Immunol, 90, 197, 10.1016/j.molimm.2017.06.018 · DOI
  24. Allin, 2009, Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer., J Clin Oncol, 27, 2217, 10.1200/JCO.2008.19.8440 · DOI
  25. Rothwell, 2011, Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials., Lancet, 377, 31, 10.1016/S0140-6736(10)62110-1 · DOI · Paper page
  26. Cuzick, 2009, Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement., Lancet Oncol, 10, 501, 10.1016/S1470-2045(09)70035-X · DOI
  27. Hassan Aref, 2014, CRP evaluation in non-small cell lung cancer., Egypt J Chest Dis Tuberculosis, 63, 717, 10.1016/j.ejcdt.2014.02.003 · DOI
  28. Kanoh, 2013, Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A., Oncol Rep, 29, 469, 10.3892/or.2012.2123 · DOI
  29. Zhou, 2015, Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer., Sci Rep, 5, 10481, 10.1038/srep10481 · DOI
  30. Elaraj, 2006, The role of interleukin 1 in growth and metastasis of human cancer xenografts., Clin Cancer Res, 12, 1088, 10.1158/1078-0432.CCR-05-1603 · DOI
  31. Gemma, 2001, Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line., Eur J Cancer, 37, 1554, 10.1016/S0959-8049(01)00154-X · DOI
  32. Tu, 2008, Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice., Cancer Cell, 14, 408, 10.1016/j.ccr.2008.10.011 · DOI
  33. Akagi, 1999, Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta., Br J Cancer, 80, 1506, 10.1038/sj.bjc.6690553 · DOI
  34. Konishi, 2005, Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma., Oncology, 68, 138, 10.1159/000086768 · DOI
  35. Carmi, 2013, The role of IL-1β in the early tumor cell-induced angiogenic response., J Immunol, 190, 3500, 10.4049/jimmunol.1202769 · DOI
  36. Krelin, 2007, Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors., Cancer Res, 67, 1062, 10.1158/0008-5472.CAN-06-2956 · DOI · Paper page
  37. Takahashi, 2010, Tobacco smoke promotes lung tumorigenesis by triggering ikkbeta- and JNK1-dependent inflammation., Cancer Cell, 17, 89, 10.1016/j.ccr.2009.12.008 · DOI
  38. Brailo, 2012, Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer., Med Oral Patol Oral Cir Bucal, 17, e10, 10.4317/medoral.17323 · DOI
  39. Chen, 1999, Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer., Clin Cancer Res, 5, 1369
  40. Kim, 2013, Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer., Cancer Res Treat, 45, 325, 10.4143/crt.2013.45.4.325 · DOI
  41. Ozyurek, 2018, Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer?, Clin Respir J, 12, 2013, 10.1111/crj.12768 · DOI
  42. Hara, 2007, Preoperative serum C-reactive protein level in non-small cell lung cancer., Anticancer Res, 27, 3001
  43. Gagné-Ouellet, 2014, Tobacco smoke induces changes in IL-1 family in bronchial epithelial cells obtained from asthmatic individuals., Allergy Asthma Clin Immunol, 10, A55, 10.1186/1710-1492-10-S2-A55 · DOI
  44. Landvik, 2009, A specific interleukin-1B haplotype correlates with high levels of IL1B mrna in the lung and increased risk of non-small cell lung cancer., Carcinogenesis, 30, 1186, 10.1093/carcin/bgp122 · DOI
  45. Eaton, 2018, Inflammatory gene polymorphisms in lung cancer susceptibility., J Thorac Oncol, 13, 649, 10.1016/j.jtho.2018.01.022 · DOI
  46. Lu, 2017, The role of checkpoint inhibition in non-small cell lung cancer., Ochsner J, 17, 379
  47. Zhou, 2015, Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)., Ann Oncol, 26, 1877, 10.1093/annonc/mdv276 · DOI · Paper page
  48. Wu, 2015, First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study., Ann Oncol, 26, 1883, 10.1093/annonc/mdv270 · DOI · Paper page
  49. Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer., N Engl J Med, 378, 113, 10.1056/NEJMoa1713137 · DOI · Paper page
  50. Yao, 2010, TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer., Proc Natl Acad Sci U S A, 107, 15535, 10.1073/pnas.1009472107 · DOI · Paper page
  51. An, 2017, Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells., Oncol Lett, 14, 3445, 10.3892/ol.2017.6613 · DOI
  52. Stanam, 2015, Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma., Mol Oncol, 9, 1371, 10.1016/j.molonc.2015.03.008 · DOI
  53. Ishibashi, 2017, Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade., Oncotarget, 8, 55230, 10.18632/oncotarget.19420 · DOI

Cited by

Sorted by citations

Metadata

Authors
Schenk, K. M., Reuss, J. E., Choquette, K., & Spira, A. I.
Affiliations
  • Johns Hopkins University (US)
  • Virginia Cancer Specialists (US)
Corresponding author
Spira, Alexander I.
ORCID
Venue
Anti-Cancer Drugs
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2019-10
Volume
30
Issue
9
Pages
879-885
ISSN
0959-4973 (ISSN-L)
DOI
10.1097/cad.0000000000000832
OpenAlex
W2973133331
Cited by
22
References
2
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 2
FWCI
0.29
Type
journal article
Language
en
Open access
closed
Locations
  • Anti-Cancer Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Keywords
canakinumab, non-small cell lung cancer, IL-1β, chronic inflammation, anti-inflammatory therapy, antibody therapy, lung cancer incidence, recurrent lung cancer, angiogenesis, metastasis
MeSH terms
Animals, Carcinoma, Non-Small-Cell Lung, Humans, Inflammation, Lung Neoplasms, Neoplasm Recurrence, Local, Incidence, Interleukin-1beta, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review